Editorial

I would like to extend my warmest New Year's greetings to all our readers as we commence the 31st volume and 30th year of publishing International Immunology. As we acknowledge and celebrate this particular milestone in the journal's history, I am very glad to be able to report on some good news from an eventful 2018. Last year saw International Immunology's Impact Factor rise to 5.189; the journal's highest Impact Factor to date and the first time it has risen above five. Several of the most highly cited papers which contributed to the Impact Factor were from our Special Issue on Antibody-Targeted Therapy, highlighting the global attention that this exciting field of research is currently receiving (1).

http://bit.ly/2DWyazY